Crocins
Serotonergic pathway
Studied for interaction with serotonergic signalling, including serotonin availability. Preclinical models also explore neuroplasticity signalling and antioxidant activity.
How crocins and safranal, the two characterized compounds in Saffrion 42™ saffron extract, are studied in preclinical research, and what placebo-controlled trials of a different saffron extract have reported so far.
Saffrion 42™ pairs two characterized saffron compounds in one extract. Preclinical research points to complementary pathways.
Serotonergic pathway
Studied for interaction with serotonergic signalling, including serotonin availability. Preclinical models also explore neuroplasticity signalling and antioxidant activity.
GABAergic pathway
Associated in preclinical research with modulation of GABAergic activity, linked to the relaxation response and neural excitability balance.
One standardized extract, two complementary research targets: emotional tone and calm.
Mechanistic descriptions summarize preclinical literature. They are not health claims for the ingredient or for finished products.
Placebo-controlled trials with a different saffron extract found improvements in some measures of mood, stress and sleep. They provide background for the category, not evidence for Saffrion 42™ itself.[1][2][3]
Read more: what the clinical trials show · saffron extract and sleep
Planned; results not yet reported. Efficacy, tolerability, dose and time to effect for this extract require dedicated data.
Results expected Q1 2027
Request technical documentation, samples and pricing.